Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Completed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

Key facts

Study ID

NCT00151333

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

16

Starts

2005-02-01

Expected to finish

2005-04-01

Last updated by the study team

2009-09-04

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
• Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.
• Able to give informed consent. Patient's caregiver must consent to participate in the study.

You may not qualify if…

• Significant neurologic disease other than AD that may affect cognition.
• Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study.
• Other exclusions apply

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Fort Lauderdale, Florida, United States
• Study site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.